#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA688356	F	Inhibitory concentration against human carcinoma HCT116 cell line	Homo sapiens	14	ALA1136395	cell-based format	Scientific Literature
2.	ALA684827	F	Percent reversion in HCT116 cell line (IC50(-)/MDR IC50(+) X 100	Homo sapiens	15	ALA1136395	cell-based format	Scientific Literature
3.	ALA687005	F	Inhibitory concentration of doxorubicin against the MDR resistant cell line HCT116/VM46 in the presence of 1 mM of the compound	Homo sapiens	14	ALA1136395	cell-based format	Scientific Literature
4.	ALA687007	F	Inhibitory concentration against MDR human carcinoma HCT116/VM46 cell line	Homo sapiens	14	ALA1136395	cell-based format	Scientific Literature
5.	ALA687008	F	Inhibitory concentration of vinblastine against the MDR resistant cell line HCT116/VM46 in the presence of 1 mM of the compound	Homo sapiens	15	ALA1136395	cell-based format	Scientific Literature
6.	ALA687010	F	Gain in sensitivity is measured as MDR IC50 (without added drug) / MDR IC50 (with added drug) in MDR HCT116/VM46 cell line	Homo sapiens	15	ALA1136395	cell-based format	Scientific Literature
7.	ALA833858	F	Intrinsic cytotoxic activity against wild type HCT116 cell line	Homo sapiens	25	ALA1137986	cell-based format	Scientific Literature
8.	ALA837818	F	Intrinsic cytotoxic activity against Multidrug resistant HCT116/VM46 cell line	Homo sapiens	22	ALA1137986	cell-based format	Scientific Literature
9.	ALA833966	F	inhibitory activity of compound against Multidrug resistant HCT116/VM46 cell line treated with Vinblastine	Homo sapiens	23	ALA1137986	cell-based format	Scientific Literature
10.	ALA825757	F	Multi drug resistance reversal in HCT116/VM46 cell line treated with Vinblastine	Homo sapiens	24	ALA1137986	cell-based format	Scientific Literature
11.	ALA4191992	B	Inhibition of P-gp in mouse P388/DOX cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring fold reduction in doxorubicin IC50	Mus musculus	1	ALA4190243	cell-based format	Scientific Literature
12.	ALA4191993	B	Inhibition of P-gp in human HCT116/VM46 cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring fold reduction in vinblastine IC50	Homo sapiens	2	ALA4190243	cell-based format	Scientific Literature
13.	ALA4192019	B	Inhibition of P-gp in human HCT116/VM46 cells assessed as potentiation of vinblastine-induced cytotoxicity at 1 uM by measuring fold reduction in vinblastine IC50 relative to control	Homo sapiens	2	ALA4190243	cell-based format	Scientific Literature
14.	ALA4192020	B	Inhibition of P-gp in human CCRF-CEM/VLB100 cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring fold reduction in vinblastine IC50	Homo sapiens	1	ALA4190243	assay format	Scientific Literature
15.	ALA4192065	B	Inhibition of P-gp in human HCT116/VM46 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring fold reduction in doxorubicin IC50	Homo sapiens	1	ALA4190243	cell-based format	Scientific Literature
16.	ALA5231976	F	Cytotoxicity against human HCT-116/VM46 cells assessed as reversal of multi drug resistance at 1 uM	Homo sapiens	4	ALA5230136	cell-based format	Scientific Literature
17.	ALA5231977	F	Cytotoxicity against human HCT-116 cells assessed as reversal of multi drug resistance at 1 uM	Homo sapiens	2	ALA5230136	cell-based format	Scientific Literature
18.	ALA5231978	F	Cytotoxicity against human L1210 cells assessed as reversal of multi drug resistance at 1 uM	Mus musculus	2	ALA5230136	cell-based format	Scientific Literature
19.	ALA5232041	F	Anticancer activity against Multi drug resistant human HCT-116/VM46 cells assessed as inhibition of cell growth	Homo sapiens	1	ALA5230136	cell-based format	Scientific Literature